Eli Lilly and Company (LLY)vsOncology Institute Inc (TOI)
LLY
Eli Lilly and Company
$963.33
+3.07%
HEALTHCARE · Cap: $760.43B
TOI
Oncology Institute Inc
$4.05
+4.92%
HEALTHCARE · Cap: $366.69M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 12865% more annual revenue ($65.18B vs $502.73M). LLY leads profitability with a 31.7% profit margin vs -12.1%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
TOI
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+80.1%
Fair Value
$13.17
Current Price
$4.05
$9.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Revenue surging 41.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -652.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : TOI
The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.6% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : TOI
The primary concerns for TOI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while TOI is a hypergrowth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 45/100), backed by strong 31.7% margins and 42.6% revenue growth. TOI offers better value entry with a 80.1% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Oncology Institute Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Oncology Institute Inc (ticker: TOI) is a pioneering healthcare organization dedicated to transforming cancer care through its extensive network of specialized clinics and innovative treatment modalities. The company prioritizes enhanced patient outcomes by leveraging state-of-the-art technologies and customized treatment plans, while also participating in clinical trials and collaborations with leading research institutions. As the need for advanced cancer therapies continues to grow, TOI is strategically positioned to leverage its robust pipeline and deep-seated oncology expertise, reinforcing its status as a key player in the evolving healthcare sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?